Tidepath

More GLP-1 drugs

Orforglipron

Also called Foundayo

A GLP-1 pill that isn't a peptide, approved in the US as Foundayo13.

Status
Approved by the FDA in 2026 for long-term weight management, as Foundayo21.
How it's taken
By mouth

What it is

Foundayo is the brand name for orforglipron, a pill approved in the US for long-term weight management1. It's for adults with obesity, or with overweight and at least one weight-related health problem, alongside a reduced-calorie diet and more physical activity1. It's a GLP-1 receptor agonist: it switches on the receptor for GLP-1, a hormone that helps control appetite and how much people eat1. The label says it lowers how much people eat, likely by lowering appetite, and slows how fast the stomach empties1. It isn't a peptide but a small molecule, a compound that isn't built from the amino acids that make up peptides and proteins3. Its half-life, the time it takes for half a dose to clear, is about 29 to 49 hours1.

What makes it distinct

Foundayo is a GLP-1 pill that isn't a peptide, and its label says to take it once a day, with or without food13.

What the evidence shows

Its US label describes two 72-week trials that compared it with a placebo, with diet and exercise advice for everyone1. ATTAIN-1 enrolled 3,127 adults with obesity, or overweight and a related health problem, who didn't have diabetes; people on orforglipron lost more weight than people on placebo13. ATTAIN-2 enrolled 1,613 adults with overweight or obesity and type 2 diabetes, with the same kind of result14. In ACHIEVE-1, 559 adults with early type 2 diabetes took it or a placebo for 40 weeks, and their HbA1c, a blood test of average blood sugar, fell more than on placebo5. ACHIEVE-4 compared it with insulin glargine, an injected insulin, in 2,749 adults with type 2 diabetes and either heart and blood vessel disease or long-term kidney disease6. People were followed for a median of two years, meaning half were followed for longer and half for less6. The trial was set up to check heart safety: to rule out a rise in major heart events, such as heart attacks and strokes, beyond a limit set before it began, compared with insulin glargine6. It met that goal6. In ATTAIN-MAINTAIN, people who had been treated with tirzepatide or semaglutide in an earlier trial switched to orforglipron or a placebo; those on orforglipron kept off more of the weight they had lost, measured at 52 weeks7. Across these trials, stomach and gut problems were the most common side effects34567. In the trials whose papers say how severe they were, they were mostly mild to moderate3457. Eli Lilly, which makes it, funded ATTAIN-1, ATTAIN-2, ACHIEVE-1 and ACHIEVE-413456.

Open questions

  • Whether it causes thyroid tumors in people. In animal studies it caused thyroid C-cell tumors (C-cells are a type of cell in the thyroid), and its label says it isn't known whether that happens in people1.
  • Whether it lowers the risk of heart attacks and strokes. ACHIEVE-4 shows heart safety compared with insulin, not a lower risk6.
  • Effects over longer periods. ACHIEVE-4 followed people for a median of two years6.
  • What happens to weight after stopping orforglipron. ATTAIN-MAINTAIN studied people switching to it from an injection, not people stopping it7.
  • How switching compares with staying on the injection. ATTAIN-MAINTAIN had no group that stayed on their injection7.

Worth knowing

Trial papers and the US label can give different numbers for the same dose136. The two trials behind the label used an investigational form of orforglipron, and the label shows their doses as the matching doses of the approved tablet1. ACHIEVE-4, for example, gives its doses for a capsule, with the matching tablet dose alongside6. In the US, its label covers weight management only1. In October 2026, a committee of the European Medicines Agency recommended approving it in the EU for weight management and for type 2 diabetes; the European Commission makes the final decision8.

Sources

  1. FOUNDAYO (orforglipron) tablets, US prescribing information (DailyMed, Eli Lilly; label updated July 2026)
  2. Drugs@FDA: NDA 220934, FOUNDAYO (orforglipron calcium)
  3. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025
  4. Horn DB et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet 2026
  5. Rosenstock J et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med 2025
  6. Klein KR et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4). Lancet 2026
  7. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the phase 3b ATTAIN-MAINTAIN trial. Nat Med 2026
  8. European Medicines Agency: Foundayo (orforglipron), summary of CHMP opinion

More in More GLP-1 drugs